135 related articles for article (PubMed ID: 11790468)
21. Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox.
Peckham EM; Barkley LM; Divin MF; Cicero TJ; Traynor JR
Brain Res; 2005 Oct; 1058(1-2):137-47. PubMed ID: 16139823
[TBL] [Abstract][Full Text] [Related]
22. Morphine metabolites.
Christrup LL
Acta Anaesthesiol Scand; 1997 Jan; 41(1 Pt 2):116-22. PubMed ID: 9061094
[TBL] [Abstract][Full Text] [Related]
23. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat.
Qian-Ling G; Hedner J; Björkman R; Hedner T
Pain; 1992 Feb; 48(2):249-255. PubMed ID: 1589243
[TBL] [Abstract][Full Text] [Related]
24. Modulation of metabolic effects of morphine-6-glucuronide by morphine-3-glucuronide.
Hashiguchi Y; Molina PE; Abumrad NN
Brain Res Bull; 1995; 38(4):325-9. PubMed ID: 8535854
[TBL] [Abstract][Full Text] [Related]
25. Randomized placebo-controlled trial of the activity of the morphine glucuronides.
Penson RT; Joel SP; Bakhshi K; Clark SJ; Langford RM; Slevin ML
Clin Pharmacol Ther; 2000 Dec; 68(6):667-76. PubMed ID: 11180027
[TBL] [Abstract][Full Text] [Related]
26. Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test.
Lötsch J; Tegeder I; Angst MS; Geisslinger G
Life Sci; 2000 May; 66(24):2393-403. PubMed ID: 10864101
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.
Dzierlenga AL; Clarke JD; Hargraves TL; Ainslie GR; Vanderah TW; Paine MF; Cherrington NJ
J Pharmacol Exp Ther; 2015 Mar; 352(3):462-70. PubMed ID: 25512370
[TBL] [Abstract][Full Text] [Related]
28. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats.
Suzuki N; Kalso E; Rosenberg PH
Eur J Pharmacol; 1993 Nov; 249(2):247-50. PubMed ID: 8287909
[TBL] [Abstract][Full Text] [Related]
29. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.
Zelcer N; van de Wetering K; Hillebrand M; Sarton E; Kuil A; Wielinga PR; Tephly T; Dahan A; Beijnen JH; Borst P
Proc Natl Acad Sci U S A; 2005 May; 102(20):7274-9. PubMed ID: 15886284
[TBL] [Abstract][Full Text] [Related]
30. The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver.
Hasegawa Y; Kishimoto S; Shibatani N; Nomura H; Ishii Y; Onishi M; Inotsume N; Takeuchi Y; Fukushima S
J Pharm Pharmacol; 2010 Mar; 62(3):310-4. PubMed ID: 20487213
[TBL] [Abstract][Full Text] [Related]
31. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat.
Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
Pharm Res; 1998 Apr; 15(4):599-605. PubMed ID: 9587957
[TBL] [Abstract][Full Text] [Related]
32. Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice.
Bian JT; Bhargava HN
Peptides; 1996; 17(8):1415-9. PubMed ID: 8971939
[TBL] [Abstract][Full Text] [Related]
33. Morphine-3-glucuronide: hyperglycemic and neuroendocrine potentiating effects.
Hashiguchi Y; Molina PE; Abumrad NN
Brain Res; 1995 Oct; 694(1-2):13-20. PubMed ID: 8974636
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetic analysis of sex differences in opioid antinociception in rats.
Terner JM; Lomas LM; Smith ES; Barrett AC; Picker MJ
Pain; 2003 Dec; 106(3):381-391. PubMed ID: 14659521
[TBL] [Abstract][Full Text] [Related]
35. Wheel running attenuates the antinociceptive properties of morphine and its metabolite, morphine-6-glucuronide, in rats.
Mathes WF; Kanarek RB
Physiol Behav; 2001 Sep 1-15; 74(1-2):245-51. PubMed ID: 11564474
[TBL] [Abstract][Full Text] [Related]
36. The influence of hemorrhagic shock on the pharmacokinetics and the analgesic effect of morphine in the rat.
De Paepe P; Belpaire FM; Rosseel MT; Buylaert WA
Fundam Clin Pharmacol; 1998; 12(6):624-30. PubMed ID: 9818295
[TBL] [Abstract][Full Text] [Related]
37. [Study of Supplementary Analgesics Capable of Reducing the Dosage of Morphine].
Komatsu T
Yakugaku Zasshi; 2016; 136(2):329-35. PubMed ID: 26831810
[TBL] [Abstract][Full Text] [Related]
38. C-Fos activation in the periaqueductal gray following acute morphine-3β-D-glucuronide or morphine administration.
Arout CA; Caldwell M; McCloskey DP; Kest B
Physiol Behav; 2014 May; 130():28-33. PubMed ID: 24631297
[TBL] [Abstract][Full Text] [Related]
39. Morphine Glucuronidation and Elimination in Intensive Care Patients: A Comparison with Healthy Volunteers.
Ahlers SJ; Välitalo PA; Peeters MY; Gulik Lv; van Dongen EP; Dahan A; Tibboel D; Knibbe CA
Anesth Analg; 2015 Nov; 121(5):1261-73. PubMed ID: 26332855
[TBL] [Abstract][Full Text] [Related]
40. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
